Gordon C. Brandt
Hoofd Techniek/Wetenschap/O&O bij Profil Institute for Clinical Research, Inc.
Profiel
Gordon C.
Brandt is a Senior Director of Clinical Development at Profil Institute for Clinical Research, Inc. He was previously the President of MDRNA, Inc. from 2002 to 2008, and Vice President of Clinical & Regulatory Affairs at Sonus Pharmaceuticals, Inc. He also served as the Chief Medical Officer at PhaseRx, Inc. from 2016 to 2017.
Brandt received his undergraduate degree from Yale University and his doctorate from The University of California, San Francisco.
Actieve functies van Gordon C. Brandt
| Bedrijven | Functie | Begin |
|---|---|---|
Profil Institute for Clinical Research, Inc.
 Profil Institute for Clinical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Profil Institute for Clinical Research, Inc. operates as a full-service clinical research organization (CRO), that focuses on diabetes, obesity and NAFLD/NASH. It offers clinical development, regulatory affair, clinical research, scientific, data management and statistical, monitoring, quality and compliance, and recruitment services. The company was founded in 2004 and is headquartered in Chula Vista, CA. | Hoofd Techniek/Wetenschap/O&O | - |
Eerdere bekende functies van Gordon C. Brandt
| Bedrijven | Functie | Einde |
|---|---|---|
| PHASERX, INC. | Hoofd Techniek/Wetenschap/O&O | 01-10-2017 |
MDRNA, Inc.
 MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | President | 30-09-2008 |
Sonus Pharmaceuticals, Inc.
 Sonus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sonus Pharmaceuticals, Inc. engaged in the development of drugs for the treatment of cancer and related therapies. Its primary product TOCOSOL Paclitaxel, was an injectable paclitaxel emulsion for nonsmall cell lung cancer, ovarian cancer and bladder cancer. Sonus Pharmaceuticals was incorporated in 1991 and was headquartered in Bothell, WA. | Corporate Officer/Principal | - |
Opleiding van Gordon C. Brandt
| Yale University | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PHASERX, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | Commercial Services |
Profil Institute for Clinical Research, Inc.
Profil Institute for Clinical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Profil Institute for Clinical Research, Inc. operates as a full-service clinical research organization (CRO), that focuses on diabetes, obesity and NAFLD/NASH. It offers clinical development, regulatory affair, clinical research, scientific, data management and statistical, monitoring, quality and compliance, and recruitment services. The company was founded in 2004 and is headquartered in Chula Vista, CA. | Commercial Services |
Sonus Pharmaceuticals, Inc.
Sonus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sonus Pharmaceuticals, Inc. engaged in the development of drugs for the treatment of cancer and related therapies. Its primary product TOCOSOL Paclitaxel, was an injectable paclitaxel emulsion for nonsmall cell lung cancer, ovarian cancer and bladder cancer. Sonus Pharmaceuticals was incorporated in 1991 and was headquartered in Bothell, WA. | Health Technology |
